Phaseline

Targets › CD73

CD73: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: the race on CD73, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GI InnovationGI-108
Anti-CD73-IgG4 Fc-IL-2v bispecific fusion protein
CD73, IL2RAPhase 1Advanced Solid TumorFeb 2027
AP BiosciencesAP601
Bispecific antibody targeting CD73
CD73Phase 1Solid TumoursDec 2027

Conditions

Solid Tumours (1) Advanced Solid Tumor (1)

Modalities

small molecule (2)

Companies

AP Biosciences (1) GI Innovation (1)

Related targets

IL2RA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.